Skip to main content

CTI BioPharma Corp. Credit Rating & Financial Statements Analysis

BOSTON (AC Invest Credit Rating Terminal) Sat Jan 22 2022 05:42:02 GMT+0000 (Coordinated Universal Time) AI Credit Ratings today took the rating actions below:

Credit Rating Rationales & Model

In this scenario, we would still include the existing debt maturity as a use of liquidity in our A/B and A-B calculations, if the debt matures within the corresponding liquidity horizon. The rationale is that our liquidity assessment is essentially a stress test against a sudden and severe loss of capital markets access availability. For companies with an anchor of at least 'bbb-' that meet certain characteristics, as outlined in paragraphs 38 and 39 of the criteria, we may use a shorter three- to six-month time horizon when assessing upcoming maturities.

Rating Model for CTI BioPharma Corp.: We estimate the credit risk parameters by Modified (Smoothed) Moving Average and Wilcoxon Rank-Sum Test

Credit Ratings for CTI BioPharma Corp. as of 22 Jan 2022

Credit Rating Short-Term Long-Term Senior
AI Rating Class*B3Ba1
Semantic Signals4974
Financial Signals6589
Risk Signals3051
Substantial Risks3752
Speculative Signals7887

*Machine Learning utilizes multiple learning algorithms to obtain better predictive powers. In our research, we utilize machine learning to combine the results from the Neural Network and Support Vector Machines.

 *AC Investment Research | Legal Disclaimer | NYSE | NASDAQ | LSE | NSE |